Skye Bioscience (SKYE) Other Working Capital Changes (2021 - 2026)
Skye Bioscience (SKYE) posted quarterly Other Working Capital Changes of -$212666.0 for Q1 2026, down 389.12% year-over-year from $73555.4 in Q1 2025, and down 341.22% quarter-over-quarter from -$48199.0 in Q4 2025.
Skye Bioscience (SKYE) Other Working Capital Changes (2021 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Other Working Capital Changes for 6 consecutive years, with -$212666.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 389.12% year-over-year to -$212666.0; the TTM figure through Mar 2026 stood at -$351131.0 (down 189.85% YoY), while the FY2025 annual figure was -$181944.0, down 92.65% from the prior year.
- Other Working Capital Changes slipped to -$212666.0 in Q1 2026 per SKYE's latest filing, from -$48199.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $1.4 million in Q2 2024 and bottomed at -$2.5 million in Q2 2025.
- Historically, Other Working Capital Changes has averaged -$10801.8 across 5 years, with a median of $30673.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Working Capital Changes soared 113.38% — and 2024, when it plunged 740.95%.
- Skye Bioscience's Other Working Capital Changes stood at -$21883.0 in 2022, then grew by 27.25% to -$15919.0 in 2023, then plunged by 164.89% to -$42168.0 in 2024, then fell by 14.3% to -$48199.0 in 2025, then slumped by 341.22% to -$212666.0 in 2026.
- Business Quant data shows SKYE's Other Working Capital Changes at -$212666.0 in Q1 2026, -$48199.0 in Q4 2025, and -$45695.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Skye Bioscience | 10.75 Mn | 10.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212,666.00 |
| Mar 31, 2026 | -212,666.00 |
| Mar 31, 2026 | -212,666.00 |
| Dec 31, 2025 | -48,199.00 |
| Dec 31, 2025 | -48,199.00 |
| Dec 31, 2025 | -48,199.00 |
| Sep 30, 2025 | -45,695.00 |
| Sep 30, 2025 | -45,695.00 |
| Sep 30, 2025 | -45,695.00 |
| Jun 30, 2025 | -44,571.00 |
| Jun 30, 2025 | -44,571.00 |
| Jun 30, 2025 | -44,571.00 |
| Mar 31, 2025 | -43,479.00 |
| Mar 31, 2025 | -43,479.00 |
| Mar 31, 2025 | -43,479.00 |
| Dec 31, 2024 | -42,168.00 |
| Dec 31, 2024 | -42,168.00 |
| Dec 31, 2024 | -42,168.00 |
| Sep 30, 2024 | -18,078.00 |
| Sep 30, 2024 | -18,078.00 |